Brian Anderson, DO
Family Medicine · Harlan, IANPI 1447231816
Payments from drug & device makers
Across 244 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$681
- Lilly USA, LLC$486
- Amgen$327
- Bayer$304
- Novartis$255
- Pfizer$210
- plus $2K from 32 others
What the payments were for
- Consulting fees$160%
- Food & beverage$4,031100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $681 |
| Lilly USA, LLC | 31 | $486 |
| Amgen | 23 | $327 |
| Bayer | 17 | $304 |
| Novartis | 14 | $255 |
| Pfizer | 12 | $210 |
| AstraZeneca | 13 | $191 |
| Boehringer Ingelheim | 11 | $178 |
| Johnson & Johnson | 11 | $156 |
| AbbVie(2 entities) | 7 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Merck | 7 | $109 |
| Eisai Inc. | 4 | $86 |
| Boston Scientific | 1 | $69 |
| Genentech USA, Inc. | 4 | $65 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Mylan Specialty L.p. | 3 | $48 |
| VBI Vaccine (delaware) Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Biogen | 2 | $36 |
| Exact Sciences | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Organogenesis Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Agile Therapeutics, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Bioxcel Therapeutics, Inc. | 1 | $19 |
| Vertex | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| GSK | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
How this compares
$4,047 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 199 | $123,878 |
| JardianceEmpagliflozin | 148 | $92,974 |
| OzempicSemaglutide | 71 | $68,683 |
| TrulicityDulaglutide | 56 | $66,074 |
| XareltoRivaroxaban | 91 | $51,336 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $28,715 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $27,445 |
| GocovriAmantadine Hcl | 12 | $19,291 |
| VraylarCariprazine Hcl | 26 | $18,584 |
| FarxigaDapagliflozin Propanediol | 19 | $16,185 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,679 |
| MounjaroTirzepatide | 12 | $12,620 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,308 |
| Potassium Chloride | 139 | $6,166 |
| Rosuvastatin Calcium | 351 | $5,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $210 | $123,878199 claims |
| Boehringer IngelheimJardiance | $178 | $92,974148 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $486 | $78,69468 claims |
| Novo NordiskOzempic | $681 | $68,68371 claims |
| Johnson & JohnsonXarelto | $156 | $51,33691 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $42,39361 claims |
| AstraZenecaFarxiga, Lokelma | $191 | $19,72632 claims |
| AbbVieVraylar | $142 | $18,58426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Harlan
- Scott MarkhamHarlan$12K
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.